Pfizer (PFE) Tops Q1 EPS by 15c, Guidance Misses Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. DAL
5. AWK
6. SPCX
7. III
8. TTEC
9. SNY

Go back to Pfizer (PFE) Tops Q1 EPS by 15c, Guidance Misses Consensus

Pfizer Reports First-Quarter 2022 Results

May 3, 2022 6:45 AM EDT

First-Quarter 2022 Revenues of $25.7 Billion, Reflecting 82% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Increased 2% Operationally First-Quarter 2022 Reported Diluted EPS(2) of $1.37 and Adjusted Diluted EPS(3) of $1.62 Both Reported(2) and Adjusted(3) Diluted EPS Include a $0.05 Negative Impact for Acquired In-Process R&D Expenses(4), Which Prior to First-Quarter 2022 Had Largely Been Excluded From Adjusted(3) Results Reaffirms Full-Year 2022 Financial Guidance(4) for Revenues of $98.0 to $102.0 Billion, Which Includes Operational Increases Offset by Approximately $2 Billion of Negative Foreign Exchange Impacts Reaffirms 2022 Revenue Guidance for Comirnaty(1) of Approximately $32 Billion, Despite a ~$1 Billion... More